@Zalotie 1 month ago
IOVA up 6% after Goldman sets $15 price target
IOVA up 6% after Goldman sets $15 price target
Goldman Sachs resumed coverage on Iovance Biotherapeutics with a buy rating and a $15 price target. The stock gained about 6% on Thursday. The analyst pointed to strong Q2 numbers for their melanoma drug Amtagvi, which generated $91 million in sales. They noted that operational roadblocks are clearing up and survey data shows solid demand for the treatment.

www.fool.com
| Why Iovance Biotherapeutics Stock Was on Fire Today | The Motley Fool
@TallDrive706 1 month ago
Amtagvi’s $91M Q2 sales are encouraging, but the key test is whether cleared operational hurdles translate into sustained demand and broader commercial growth.
@Nathan956 1 month ago
I am curious to see if Iovance Biotherapeutics can keep this momentum going through the rest of the year.